ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
June 03 2019 - 7:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of biologic
therapies for life-threatening, drug-resistant infectious diseases,
today announced that Cara Cassino, M.D., Chief Medical Officer and
Executive Vice President of Research and Development at ContraFect,
will present at the invitation of the International Society of
Cardiovascular Infectious Diseases (ISCVID) Symposium on Monday,
June 3, 2019, in Lausanne, Switzerland. Dr. Cassino will discuss
ContraFect’s lead phage-derived lysin candidate, exebacase, and
promising data on the treatment of patients with
methicillin-resistant Staphylococcus aureus (MRSA) bloodstream
infections, including endocarditis, from the Company’s Phase 2
clinical trial.
Presentation Details:
Presentation Title: Novel Phage Lysins
for MRSA IESession Day &
Time: Monday, June 3, 2019 at 3:30 p.m. CEST
Session Title: Novel Therapeutic Strategies
(Including Experimental)
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of direct
lytic agents (DLAs), which include lysins and amurin peptides.
Lysins are a new therapeutic class of DLAs derived from
bacteriophage which are recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics. We believe that the properties of
our lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staphylococcus aureus
(Staph aureus) and Pseudomonas Aeruginosa (P. Aeruginosa), which
can cause serious infections such as bacteremia, pneumonia and
osteomyelitis. We have clinically completed a Phase 2 clinical
trial for the treatment of Staph aureus bacteremia, including
endocarditis with our lead lysin candidate, exebacase (CF-301),
which is the first lysin to enter clinical studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
About Exebacase (CF-301):
Exebacase (CF-301) is a recombinantly-produced
lysin (cell wall hydrolase enzyme) with potent bactericidal
activity against Staph aureus, a major cause of blood stream
infections (BSIs) also known as bacteremia. Exebacase has the
potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus. By targeting a conserved
region of the cell wall that is vital to bacteria, resistance is
less likely to develop to exebacase. In addition, in vitro and in
vivo experiments have shown that exebacase is highly active against
biofilms which complicate Staph aureus infections. Exebacase was
licensed from The Rockefeller University and is being developed at
ContraFect.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the Company’s
ability to discover and develop differentiated biological
therapies for life-threatening, drug-resistant infectious diseases,
whether the data from the Phase 2 trial was promising, information
provided regarding the presentation, the Company’s ability to
address life threatening infections using its therapeutic product
candidates from its DLA platform which includes lysins and amurins,
whether lysins are a new therapeutic class of DLAs derived from
bacteriophage which are recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics, whether the properties of the
Company’s lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staph aureus and P.
aeruginosa, whether exebacase has the potential to be a
first-in-class treatment for Staph aureus bacteremia and whether
exebacase is highly active against biofilms which complicate Staph
aureus infections. Forward-looking statements are statements that
are not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024